Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM1TMA3)

Drug Name
Imiquimod Drug Info
Synonyms
Aldara; Beselna; Zartra; Zyclara; Imiquimod acetate; R 837; S 26308; Aldara (TN); Aldara, Imiquimod; Beselna (TN); DZ-2636; Imiquimod [USAN:INN]; MTD-39; R-837; S-26308; TMX-101; Imiquimod (JAN/USAN/INN); 1-(2-Methylpropyl)-1H-imidazole[4,5-c]quinoline-4-amine; 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine; 1-(2-methylpropyl)imidazo[4,5-c]quinolin-4-amine; 1-isobutyl-1H-imidazo(4,5-c)quinolin-4-amine; 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine; 3M Brand of Imiquimod; 4-Amino-1-isobutyl-1H-imidazo(4,5-c)quinoline; 4-Amino-1-isobutyl-1H-imidazo[4,5-c]quinoline
Therapeutic ClassAntiviral Agents
Cross-matching ID
PubChem CID
57469
ChEBI ID
CHEMBL1282
CAS Number
CAS 99011-02-6
TTD Drug ID
D06CTE
INTEDE Drug ID
DR0864

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Renin-angiotensin system 1.77 2.33e-1 20/23 (86.96%) MME;CPA3;KLK2;...
Epithelial cell signaling in Helicobacter pylori infect... 1.76 1.27e-1 62/70 (88.57%) CXCL1;CXCL8;CXCL3;...
IL-17 signaling pathway 1.72 1.59e-1 84/94 (89.36%) S100A7;CXCL1;CXCL8;...
Inflammatory mediator regulation of TRP channels 1.69 1.80e-1 82/98 (83.67%) PRKCB;SRC;GNAS;...
Spliceosome 1.67 1.63e-1 101/150 (67.33%) HSPA8;LSM2;EIF4A3;...
Progesterone-mediated oocyte maturation 1.63 1.93e-1 75/100 (75%) PLK1;MAPK14;CCNA2;...
Graft-versus-host disease 1.63 1.67e-1 32/42 (76.19%) GZMB;IL1B;PRF1;...
Gap junction 1.61 1.79e-1 72/88 (81.82%) PRKCB;SRC;GNAS;...
Long-term potentiation 1.60 1.79e-1 61/67 (91.04%) PRKCB;ITPR1;RAP1B;...
DNA replication 1.59 1.62e-1 34/36 (94.44%) SSBP1;RPA2;PRIM1;...
Type I diabetes mellitus 1.59 1.47e-1 38/43 (88.37%) GZMB;IL1B;HSPD1;...
RNA transport 1.58 1.48e-1 128/186 (68.82%) EIF2S1;NUP37;RAN;...
Natural killer cell mediated cytotoxicity 1.55 1.79e-1 99/131 (75.57%) PRKCB;GZMB;PAK1;...
Oocyte meiosis 1.54 1.73e-1 90/129 (69.77%) PLK1;ITPR1;MAPK14;...
Parkinson disease 1.54 1.62e-1 176/249 (70.68%) DAXX;GNAS;ITPR1;...
Gastric acid secretion 1.54 1.56e-1 63/76 (82.89%) PRKCB;GNAS;ITPR1;...
Chemokine signaling pathway 1.50 1.98e-1 163/192 (84.9%) PRKCB;CXCL1;CXCL8;...
Antigen processing and presentation 1.49 2.08e-1 60/78 (76.92%) HSPA8;NFYA;CD74;...
Oxytocin signaling pathway 1.48 2.09e-1 128/154 (83.12%) PRKCB;SRC;RCAN1;...
Long-term depression 1.47 2.20e-1 55/60 (91.67%) PRKCB;GNAS;ITPR1;...
Rheumatoid arthritis 1.47 2.10e-1 78/93 (83.87%) CXCL1;CXCL8;CXCL3;...
Fc gamma R-mediated phagocytosis 1.45 2.20e-1 79/97 (81.44%) PRKCB;PAK1;PRKCA;...
NOD-like receptor signaling pathway 1.45 2.23e-1 145/181 (80.11%) CXCL1;CXCL8;CXCL3;...
TNF signaling pathway 1.44 2.22e-1 103/112 (91.96%) CXCL1;CXCL3;CXCL2;...
Mismatch repair 1.44 2.20e-1 22/23 (95.65%) SSBP1;RPA2;MSH2;...
African trypanosomiasis 1.39 2.57e-1 32/37 (86.49%) PRKCB;PRKCA;IL1B;...
Citrate cycle (TCA cycle) 1.33 2.58e-1 30/30 (100%) IDH2;OGDHL;SUCLG2;...
VEGF signaling pathway 1.33 2.58e-1 50/59 (84.75%) PRKCB;SRC;PRKCA;...
Aminoacyl-tRNA biosynthesis 1.32 2.55e-1 15/66 (22.73%) IARS2;QRSL1;DARS2;...
Human cytomegalovirus infection 1.32 2.50e-1 201/225 (89.33%) PRKCB;CXCL8;SRC;...
Thyroid cancer -1.30 3.52e-1 36/37 (97.3%) RET;HRAS;GADD45G;...
Insulin resistance -1.30 3.54e-1 96/108 (88.89%) SLC2A1;PPP1R3C;GFPT2;...
Collecting duct acid secretion -1.31 3.57e-1 22/27 (81.48%) ATP6V1D;ATP6V1A;ATP6V0C;...
MicroRNAs in cancer -1.32 3.52e-1 146/310 (47.1%) MDM4;EFNA1;BCL2L11;...
Arachidonic acid metabolism -1.33 3.43e-1 48/61 (78.69%) PLA2G12A;GGT5;HPGDS;...
Caffeine metabolism -1.34 3.47e-1 5/6 (83.33%) XDH;CYP2A6
Steroid biosynthesis -1.34 3.41e-1 19/20 (95%) CYP27B1;SQLE;SOAT1;...
Longevity regulating pathway -1.35 3.50e-1 90/151 (59.6%) HRAS;HSPA6;AKT1;...
AMPK signaling pathway -1.37 3.04e-1 106/120 (88.33%) TSC1;CD36;IRS1;...
Lysosome -1.38 3.02e-1 115/128 (89.84%) SLC17A5;ATP6V0A2;NEU1;...
Notch signaling pathway -1.38 3.08e-1 49/59 (83.05%) JAG2;DVL1;KAT2B;...
Insulin signaling pathway -1.38 3.17e-1 121/137 (88.32%) HRAS;PHKG1;ARAF;...
Synaptic vesicle cycle -1.39 3.20e-1 63/78 (80.77%) SLC6A9;SLC6A3;AP2A2;...
Adipocytokine signaling pathway -1.40 3.17e-1 64/69 (92.75%) SLC2A1;CD36;IRS1;...
Cardiac muscle contraction -1.40 3.28e-1 64/87 (73.56%) MYH6;TRDN;ATP2A2;...
Endometrial cancer -1.40 3.43e-1 56/58 (96.55%) HRAS;APC2;ARAF;...
ABC transporters -1.41 3.48e-1 37/45 (82.22%) ABCD2;ABCA7;ABCG1;...
Selenocompound metabolism -1.44 3.15e-1 11/17 (64.71%) SCLY;PAPSS2;TXNRD1;...
Neomycin, kanamycin and gentamicin biosynthesis -1.45 3.17e-1 5/5 (100%) GCK;HK1;HKDC1
Glycerophospholipid metabolism -1.49 2.61e-1 71/98 (72.45%) CHPT1;PLA2G5;PISD;...
Pertussis -1.50 2.63e-1 64/76 (84.21%) PYCARD;ITGB2;C4BPB;...
Autophagy -1.50 2.88e-1 113/169 (66.86%) LAMP2;HRAS;GABARAPL1;...
PPAR signaling pathway -1.50 3.20e-1 66/74 (89.19%) UCP1;ACSL4;FADS2;...
Glycerolipid metabolism -1.52 3.11e-1 44/61 (72.13%) DGAT1;AKR1A1;MBOAT2;...
Dilated cardiomyopathy -1.53 3.39e-1 86/96 (89.58%) SGCG;LMNA;SGCA;...
Ferroptosis -1.59 2.16e-1 36/41 (87.8%) GPX4;CP;STEAP3;...
Amino sugar and nucleotide sugar metabolism -1.61 2.24e-1 38/48 (79.17%) NPL;HK1;GALT;...
Phagosome -1.63 2.17e-1 118/152 (77.63%) LAMP2;SEC61A1;HLA-DQB1;...
Hypertrophic cardiomyopathy -1.64 2.80e-1 81/90 (90%) SGCG;LMNA;SGCA;...
Sulfur metabolism -1.74 3.17e-1 9/10 (90%) BPNT1;SELENBP1;TST;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-673 CVCL_0080 Homo sapiens 10uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 3H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CL-34 CVCL_1123 Homo sapiens 10uM 6H
HT-29 CVCL_0320 Homo sapiens 0.04uM - 10uM 6H, 24H
LoVo CVCL_0399 Homo sapiens 10uM 6H
MDST8 CVCL_1400 Homo sapiens 10uM 6H
NCI-H508 CVCL_1561 Homo sapiens 10uM 6H
SNU-1040 CVCL_5001 Homo sapiens 10uM 6H
SNU-C4 CVCL_5008 Homo sapiens 10uM 6H
SNU-C5 CVCL_5009 Homo sapiens 10uM 6H
SW480 CVCL_0546 Homo sapiens 10uM 6H
SW620 CVCL_0547 Homo sapiens 10uM 6H
SW948 CVCL_0550 Homo sapiens 10uM 6H
Colorectal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCT 116 CVCL_0291 Homo sapiens 10uM 6H
HT115 CVCL_1294 Homo sapiens 10uM 6H
RKO CVCL_0504 Homo sapiens 10uM 6H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 10uM 6H
SNG-M CVCL_1707 Homo sapiens 10uM 6H
Endometrial carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHUEM-2 CVCL_1327 Homo sapiens 10uM 6H
Fibroblast
Nasopharyngeal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
FIBRNPC CVCL_UK07 Homo sapiens 10uM 6H, 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 0.04uM - 10uM 6H, 24H
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 15uM 72H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H
DV-90 CVCL_1184 Homo sapiens 10uM 6H
SK-LU-1 CVCL_0624 Homo sapiens 10uM 6H
Lung adenosquamous carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H596 CVCL_1571 Homo sapiens 10uM 6H
Lung large cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
COR-L23 CVCL_1133 Homo sapiens 10uM 6H
T3M-10 CVCL_1729 Homo sapiens 10uM 6H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC15 CVCL_1253 Homo sapiens 10uM 6H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1299 CVCL_0060 Homo sapiens 10uM 6H
HCC515 CVCL_5134 Homo sapiens 0.04uM - 10uM 6H, 24H
NCI-H2073 CVCL_1523 Homo sapiens 10uM 6H
Small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1694 CVCL_1495 Homo sapiens 10uM 6H
NCI-H1836 CVCL_1502 Homo sapiens 10uM 6H
Lymph node
Diffuse large B-cell lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
WSU-DLCL2 CVCL_1787 Homo sapiens 10uM 6H
Ovary
Ovarian carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
EFO-27 CVCL_1194 Homo sapiens 10uM 6H
OV7 CVCL_1623 Homo sapiens 10uM 6H
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
RMG-I CVCL_1663 Homo sapiens 10uM 6H
Ovarian mucinous cystadenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
COV644 CVCL_2011 Homo sapiens 10uM 6H
RMUG-S CVCL_1666 Homo sapiens 10uM 6H
Ovarian undifferentiated carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
TYK-nu CVCL_1774 Homo sapiens 10uM 6H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 10uM 6H
Acute myeloid leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NOMO-1 CVCL_1609 Homo sapiens 10uM 6H
PL-21 CVCL_2161 Homo sapiens 10uM 6H
SKM-1 CVCL_0010 Homo sapiens 10uM 6H
Pleural effusion
Histiocytic lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-937 CVCL_0007 Homo sapiens 10uM 6H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H
SK-MEL-1 CVCL_0523 Homo sapiens 10uM 6H
SK-MEL-28 CVCL_0526 Homo sapiens 10uM 6H
Stomach
Gastric adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
AGS CVCL_0139 Homo sapiens 10uM 6H